

Childhood Obesity

JENNIFER MILLER, ARLAN ROSENBLOOM, AND JANET SILVERSTEIN

Department of Pediatrics, Division of Endocrinology, University of Florida, Gainesville, Florida 32608

Obesity has become a pandemic, with more than a billion people affected worldwide (1). Over the past 30 yr, the frequency of overweight children, defined as a body mass index (BMI) greater than the 85th percentile for age and sex, has tripled (2). More than 30% of children in the United States are overweight or obese (BMI > 95th percentile) (3). Data from the International Obesity Task Force indicate that 22 million of the world's children under 5 yr of age are overweight or obese (4). Obesity has replaced malnutrition as the major nutritional problem in some parts of Africa, with overweight/obesity being as much as four times more common than malnutrition (5).

More than two thirds of children 10 yr and older who are obese will become obese adults (6, 7). Obesity in young adults decreases life expectancy by 5–20 yr (8). Pediatric obesity-related hospital costs have increased 3-fold during the past 20 yr, reaching \$127 million per year, and continue to rise (9, 10). The increased frequency and severity of childhood obesity is accompanied by the expected medical complications. One in four overweight children in the 6- to 12-yr age group has impaired glucose tolerance, and 60% of these children have at least one risk factor for heart disease (11). Childhood obesity threatens to thwart the reduction in cardiovascular mortality achieved over the past decades through control of hypertension, hyperlipidemia, and smoking.

Nature or Nurture?

The increased incidence of childhood obesity cannot be blamed on either environment or genetics alone. Changes in the environment (*i.e.* nutrition and lifestyle) are primarily responsible for the current epidemic in the United States because it is not possible for the gene pool to change in less than a generation.

The past few decades have brought marked lifestyle changes throughout the world, which have resulted in a decrease in physical activity and an increase in caloric intake. Children use automobiles and other automated means of transportation, including elevators and escalators, rather than walking or climbing stairs to get from place to place. The amount of time that children spend playing outside has diminished over the past few decades, and physical education programs in the schools have been reduced or eliminated (12). The majority of families now have both parents

or the single parent working, resulting in the need to find nonparental supervision after school. Fear of children playing outside without adult supervision has led many parents to admonish their children to stay inside after school. Children are thus spending more time watching television and playing on the computer than exercising (13). Television watching has been directly linked to obesity in childhood, with a rate of obesity that is 8.3 times greater in children who watch over 5 h of television per day compared with those who watch 2 h or less of television per day (14). Many parents rely on schools to provide their children with appropriate exercise, but only 25% of students participate in daily physical education classes (15). Only 22% of American children meet basic activity level recommendations, and 25% of American children are classified as completely sedentary (16).

Changes in diet have also contributed to pediatric obesity. Portion sizes in food outlets have more than doubled over the past two decades (17). In addition to a baseline increase in portion sizes, most fast food restaurants offer up to 20% larger portion sizes for minimal additional cost, adding hundreds of extra calories. Fast food is marketed to children using toys, music, and social icons. Studies have found that children's food preferences are influenced by just 30-sec exposures to television commercials (18). One third of American children age 4–19 yr eats fast food daily; it is estimated that this increases their weight by 6 lb/yr (19). Additionally, many schools now offer fast food concessions as an alternative to school lunch. Even children who receive free school lunches will spend their money to buy preferred high-fat food. The schools receive financial incentives to allow vending machines, thus providing increased availability of soda, juice, snack cakes, and chips.

The genetic component of obesity has been demonstrated by twin and adoption studies. Twin analysis indicates a heritability of fat mass of 40–70% (20). Adopted children have BMIs that correlate to those of their biological parents but not to the fat mass of their adoptive parents (21). These findings indicate that, although environment plays a crucial role in the development of childhood obesity, genetic background is also important.

The thrifty genotype hypothesis was advanced over 40 yr ago to explain the modern emergence of obesity and type 2 diabetes (22). This hypothesis postulates that humans survived by the genetic selection of those whose metabolic storage capabilities permitted survival during periods of famine by taking advantage of episodic periods of plenty in a feast and famine existence. Continuous feasting with an abundance of calorie-rich foods results in fat deposition without

Abbreviations: BMI, Body mass index; LDL, low-density lipoprotein; PYY, peptide YY3–36.

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

the concomitant period of fasting to maintain a normal body weight. Historically, only the prosperous met this condition, but modern food production and marketing have led to low-cost abundance, with obesity now disproportionately affecting those at the less prosperous end of the economic scale.

The environmental counterpart to the thrifty genotype hypothesis, the thrifty phenotype concept, has more recently been proposed to explain epidemiological evidence that metabolic programming can occur as a result of *in utero* environmental exposures (23). Small-for-gestational age babies have an increased incidence of adverse health outcomes later in life associated with insulin resistance, including type 2 diabetes, obesity, and cardiovascular disease. The thrifty phenotype hypothesis of obesity postulates that poor nutrition in fetal life is detrimental to the development and function of β -cells and insulin-sensitive tissues, resulting in emergence of insulin resistance or the metabolic syndrome later in life (24).

Maternal malnutrition, intrauterine exposure to elevated insulin levels, and early introduction of high-carbohydrate formula all result in a hyperinsulinemic state in infant mice, which persists through adulthood (25). Molecular adaptations are observed in the islet cells, liver, and adipose tissue of these rats. When the hyperinsulinemia occurs during a period of brain development, disorganization is seen in the ventromedial hypothalamic nuclei of these rats, leading to alterations in body weight, blood pressure, and glucose metabolism (25). Data from these rat models suggest that nutritional alterations early in life, such as overfeeding of formula and early introduction of high-carbohydrate foods, may contribute to metabolic programming, leading to obesity, diabetes, and early cardiovascular disease in humans.

The results of these rodent studies are consistent with observations that breastfeeding in humans may be protective against childhood obesity. Possible mechanisms for this protective effect include metabolic programming or early learned self-regulation of food intake (26). Infants who were bottle fed before 3 months of age consistently had higher BMIs and skinfold thickness during early childhood than those infants who were breastfed longer than 3 months (27). Nonetheless, all of the studies examining the protectiveness of breastfeeding have concluded that environmental and genetic factors, such as maternal weight and socioeconomic status, also play a role in the development of obesity in childhood (28).

Neuroendocrine Control of Obesity

The intricacies of the neuroendocrine control of weight, specifically the signaling pathways between the adipose tissue and the brain, are being investigated (Fig. 1). Complex interactions exist between the systems that control intake and satiety and those that control relative fat mass. Some instances of severe, early-onset, morbid obesity may result from defects in genes encoding adipose-derived hormones such as leptin, neuropeptides such as proopiomelanocortin, cocaine- and amphetamine-regulated transcript (CART), and melanocortin-4, or the receptors for these ligands (Table 1) (29). Although most of these monogenetic causes of obesity

are rare, one study showed that as many as 4% of children who become obese before the age of 10 yr have a melanocortin-4 receptor defect (30). As evaluations for genetic etiologies of obesity become more available, the screening for these known causes of obesity may become routine.

Metabolic Consequences of Obesity

As the incidence of childhood obesity has increased, so has the identification of the consequences of obesity in children, including obstructive sleep apnea, orthopedic problems, hyperandrogenism, type 2 diabetes, and cardiovascular disease. Children who develop these conditions track them into adulthood, thus increasing both their medical burden on society and their risk for early morbidity and mortality (31).

Type 2 diabetes

The increase in incidence of type 2 diabetes in children parallels the increase in the prevalence and severity of pediatric obesity (32). In North America, African-Americans, Mexican-Americans, and Native-Americans are disproportionately affected (33). African-Americans are from 1.4–2.2 times more likely to have type 2 diabetes than white persons, whereas the prevalence of type 2 diabetes in Native-Americans is 2.8 times the overall rate in North America. In one center, up to 75% of the cases of type 2 diabetes were African-American children, and this experience has been replicated in other centers (34). Whereas in 1990 only 4% of newly diagnosed childhood diabetes was type 2, by 2001 the proportion was 45% in adolescents in areas with a large population of African-American, Mexican-American, or Native-American children (35). The higher incidence of type 2 diabetes in these ethnic groups is partially due to their high rates of obesity; studies of African-American children and Pima Indians have suggested a genetic basis for this finding (36). African-American children do not have the compensatory increase in insulin secretion that is noted in Caucasian children in response to the high levels of GH during puberty (37). Additionally, insulin sensitivity is less and resting metabolic rate is lower in African-American children than in white children matched for age, sex, and BMI (37, 38). Insulin resistance is greater in Pima Indian children who later developed diabetes than in matched Pima controls (39). Additionally, certain minorities have much higher rates of diabetes-related complications and death (40). For example, African-Americans are 2.6 times more likely than whites to develop end-stage renal disease and retinopathy with type 2 diabetes (41).

Type 2 diabetes in youth is more common in girls than in boys, with one study showing that up to 80% of children who develop type 2 diabetes are female (42). Girls carry 26% more sc fat than boys, which may contribute to relative insulin resistance in the female population. Girls are less insulin sensitive than boys as early as 5 yr of age (42). Thus, sex-linked genes may contribute to insulin resistance with later development of type 2 diabetes and the metabolic syndrome in the current food-rich environment.

Approximately 17 million Americans have type 2 diabetes, and an additional 16 million Americans have insulin resistance, or prediabetes, associated with obesity (43). The adi-




FIG. 1. Neuroendocrine control of body weight. *Dashed lines* indicate net inhibitory effect. *Solid lines* indicate net stimulatory effect. ARC, Arcuate nucleus; AGRP, agouti related protein; VMN, ventromedial nucleus; NPY, neuropeptides Y; POMC, proopiomelanocortin; MC4, melanocortin-4; CART, cocaine- and amphetamine-regulated transcript; PP, pancreatic polypeptide; PYY3–36, peptide YY3–36; CCK, cholecystokinin; GLP-1, glucagon-like peptide; LHA, lateral hypothalamic area; PVN, paraventricular nucleus; DMN, dorsomedial nucleus.

pocyte is the major contributor to the development of insulin resistance and the metabolic syndrome. The relationship between obesity and insulin resistance was originally explained by lipotoxicity (44). The lipotoxicity theory states that accumulation of excess fat in the muscle cells and hepatocytes interferes with insulin signaling, leading to the development of hyperglycemia and glucose intolerance. It is now known, however, that adipose tissue secretes a number of bioactive molecules, termed adipokines (29). The adipokines include proteins and cytokines that are associated with insulin metabolism (Fig. 2). TNF α and IL-6 are proinflammatory adipokines that play a direct role in insulin resistance by inhibiting insulin action (45). These adipokines contribute to a hypercoagulable state by stimulating the release of acute-phase reactants and by promoting the release of vascular

adhesion molecules. Other adipokines, however, including adiponectin and leptin, actually improve insulin sensitivity (45). Whereas elevated leptin levels are associated with vascular dysfunction, adiponectin appears to be an endogenous antiinflammatory and antiatherogenic compound (46).

The metabolic syndrome includes type 2 diabetes, hypertension, dyslipidemia, and a prothrombotic, inflammatory vascular environment (Table 2) (47). Obesity plays a central role in the development of the metabolic syndrome, which increases the risk for development of cardiovascular disease. Those individuals who have the components of the metabolic syndrome in youth continue with them into adulthood (48). The lipid profile associated with the metabolic syndrome puts individuals at increased risk for cardiovascular disease. The characteristic lipid profile includes hypertriglyceride-

TABLE 1. Known monogenetic causes of obesity

	Leptin deficiency	Leptin receptor mutation	Melanocortin-4 receptor mutation	Proopiomelanocortin	Pseudohypoparathyroidism
Phenotype	EMO, hyperphagia, decreased T-cell function and number	EMO, hyperphagia, aggressive food-seeking behavior	EMO, tall stature, increased lean muscle mass; phenotype improves with time (adults report less intense hunger and have decreased insulin resistance)	EMO, hyperphagia, red hair	EMO, hyperphagia, can have tall stature
Endocrine abnormalities	Hypogonadotropic hypogonadism, hyperinsulinemia, hypothyroidism	Central hypothyroidism, low GH and IGF-I, absence of puberty	Hyperinsulinemia	Hypocortisolism, hypoglycemia	Primary hypothyroidism
EMO, Early-onset morbid obesity.					

mia, reduced high-density lipoprotein cholesterol, and elevated levels of small, dense low-density lipoprotein (LDL) particles. The most recent epidemiologic data show that 4% of all adolescents and 30% of overweight adolescents in the United States have the metabolic syndrome (49). The fact that the metabolic syndrome is being identified in children suggests that the development of cardiovascular disease will also occur earlier.

Cardiovascular consequences of obesity

Childhood risk factors predict later development of cardiovascular disease. The Muscatine Study demonstrated that cardiovascular risk in adults is related to childhood LDL cholesterol levels and childhood BMI in females (50). The Cardiovascular Risk in Young Finns Study also showed that childhood LDL cholesterol and BMI correlated with adult cardiovascular disease (51). The increased cardiovascular risk in adulthood was irrespective of adult risk factor status, indicating that permanent damage to the arterial wall may occur during childhood. Postmortem studies in children showed that 50% of children age 2–15 yr had fatty streaks in their coronary arteries, and 8% of these children had raised fibrous plaques in their coronary arteries (52). The Pathobiological Determinants of Atherosclerosis in Youth study found that 12% of adolescents age 15–19 yr had raised lesions or advanced lesions of atherosclerosis in their right coronary arteries (53). In both of these postmortem studies, the extent and severity of lesions correlated with BMI and lipoprotein levels.

Endothelial dysfunction is one of the earliest signs of increased risk for cardiovascular disease and has been shown to be predictive of cardiovascular events (54). Endothelial dysfunction develops in the milieu of cardiovascular risk factors such as obesity, hypertension, dyslipidemia, insulin resistance, and type 2 diabetes (55). In obese children, endothelial dysfunction is related to the severity of obesity, as well as to the degree of insulin resistance (56).

Dysfunctional endothelium produces increased levels of cytokines and cellular adhesion molecules. The cytokines and cellular adhesion molecules mediate the recruitment of macrophages and leukocytes, which then accumulate in the intima of the vessel wall, initiating the formation of atherosclerotic plaques (57). Activation of the endothelium results in a proinflammatory, procoagulant, proadhesive surface and reduced nitric oxide availability, thereby decreasing nitric oxide-dependent processes, such as inhibition of platelet aggregation and coagulation and activation of fibrinolysis (58). Unopposed atherogenic factors promote atherogenesis and thrombosis (Fig. 3).

With the exception of adiponectin, all of the adipokines appear to contribute to endothelial dysfunction (59, 60). Adiponectin is underexpressed in individuals with obesity or type 2 diabetes (61). Adiponectin decreases endothelial inflammation, inhibits vascular smooth muscle proliferation, and suppresses transformation of macrophages to foam cells (60). Adiponectin concentration is inversely related to other markers of inflammation, and low levels of adiponectin are associated with increased cardiovascular risk (62).

FIG. 2. Effects of adipokines on insulin metabolism. *Dashed lines*, Increases in adipose tissue cause increased insulin resistance.




TABLE 2. Definition of the metabolic syndrome

NCEP (ATP III) Must have 3 of 5 risk factors	WHO criteria
Abdominal obesity: waist circumference, >102 cm in men; >88 cm in women	Dysglycemia: type 2 diabetes or impaired fasting glucose or impaired glucose tolerance.+2 other criteria
Hypertriglyceridemia: >150 mg/dl (1.69 mmol/liter)	Obesity
Low HDL cholesterol: <40 mg/dl in men, <50 mg/dl in women	Dyslipidemia
High blood pressure: ≥130/85 mm Hg	Hypertension
High fasting glucose: ≥110 mg/dl (6.1 mmol/liter)	Microalbuminuria

NCEP, National Cholesterol Education Program; ATP, Adult Treatment Panel; WHO, World Health Organization; HDL, high-density lipoprotein.

Treatment of Childhood Obesity

Prevention of obesity in children should be the first line of treatment. In 2003, the American Academy of Pediatrics (AAP) issued a policy statement on prevention of pediatric overweight and obesity. This statement recommended health supervision and advocacy to prevent obesity in children. The AAP states that pediatricians should become adept at recognizing children at risk for obesity, calculate and plot BMI at all visits, use change in BMI to identify excessive weight gain, and monitor for comorbidities associated with obesity. Additionally, the AAP states that pediatricians should encourage, support, and protect breastfeeding, promote healthy eating habits, promote physical activity, and recommend limitation of television viewing. The policy statement also encourages pediatricians to become advocates for the prevention of obesity by identifying and targeting influential people for education on obesity and by directing funding toward the prevention of obesity in children.

If obesity is not prevented, the cornerstone of treatment for childhood obesity is modification of dietary and exercise habits (63). Decreasing portion sizes, decreasing high-calorie

food and drinks, and decreasing snacks are the most common dietary recommendations for obese children. However, diet modification alone is not sufficient to achieve weight loss. When caloric intake decreases, metabolism slows, resulting in decreased calorie utilization and difficulty achieving weight loss. Therefore, exercise is vital for weight loss (64). The Centers for Disease Control and Prevention recommends 30 min of moderate-intensity exercise 7 d/wk for every person in the United States (65). For those individuals attempting to achieve weight loss, the Institute of Medicine recommends 60 min of moderate-intensity exercise 7 d/wk (64). To achieve these recommendations, perceived barriers to exercise, such as lack of motivation, lack of time, and lack of support, must be overcome (66). The benefits of exercise include improved metabolic state with increased insulin sensitivity, cardiovascular fitness, and maintenance of weight loss (67). Exercise for 30 min/d results in improvements in endothelial function and inflammatory markers (68). Japanese researchers showed a halving of cardiovascular risk from just 1 h/wk of exercise (69).

Fewer than 5% of people who attempt diet and exercise




FIG. 3. Mechanisms of endothelial dysfunction and formation of atherosclerotic plaques.

modifications to lose weight actually lose a substantial amount of weight and maintain that weight loss (70). Greater than 90% of people regain their weight within 1 yr. Psychological intervention is often necessary to help patients initiate and maintain behavior change.

Although lifestyle modification is the gold standard for achievement and maintenance of weight loss, dismal long-term success results in many obese individuals turning to fad diets, pharmacotherapy, or surgery to lose weight. These options have not been proven to be safe or successful in children, but many parents, children, and practitioners are so desperate to achieve weight loss that they are willing to try anything.

The two most popular diets are the low-calorie, low-fat diet (hypocaloric diet) and the low-carbohydrate diet (71). The long-term safety and efficacy of these diets have not been evaluated in children, but studies have shown that the implementation of either of these diets in young children (ages 3–5 yr) results in an increase in obesity in the teenage years (72). In adults, both types of diet result in weight loss, decreased blood pressure, and reduced insulin resistance (73). The low-carbohydrate diet, however, resulted in greater improvements in high-density lipoprotein and triglyceride levels than the hypocaloric diet. Adults who are obese and insulin sensitive lose more weight on hypocaloric diets, whereas those who are obese and insulin resistant lose more weight on low-carbohydrate diets (74).

Pharmacologic therapy for obesity is an option that is limited to those individuals with serious comorbidities due to obesity who have failed lifestyle modification despite intensive effort by the healthcare team. None of the medications currently available for treatment of obesity are approved for children. The two most popular available medications are orlistat, an intestinal lipase inhibitor, and sibutramine, a central appetite regulator (75). Both of these

medications result in a 5–10% initial loss of weight in adult patients, with a concomitant decrease in insulin resistance and other cardiovascular risk factors (76). However, weight is regained upon discontinuation of these medications (77). Long-term studies have not been done to evaluate the effects of these medications on mortality and cardiovascular morbidity. Trials using orlistat in the pediatric population are underway.

Other potential pharmacologic therapies for obesity include topiramate, peptide YY3–36 (PYY), and metformin. Topiramate is an anticonvulsant that induces weight loss. Although the effects of topiramate on weight loss are promising, the side effects, which include depression and difficulty with memory and concentration, make this medication unlikely to be acceptable for children (78). PYY is a gut-derived peptide that modulates appetite circuits in the hypothalamus. PYY levels are low in obese individuals, and the administration of this hormone reduces food intake (79). Pharmacologic manipulation of other gut-derived hormones and peptides related to hunger and satiety is being studied. Metformin (Glucophage; Bristol-Myers Squibb Company, Princeton, NJ) use is associated with weight loss in adults with polycystic ovarian syndrome and type 2 diabetes (80). This medication is currently being evaluated for efficacy of weight loss in children who are overweight and have features of the metabolic syndrome.

Surgery is the last alternative for patients who have severe obesity-related health problems and have failed lifestyle modification and medication. Gastric bypass, the original surgical procedure for weight loss, resulted in a high rate of complications including nutrient malabsorption and even death (81). Newer techniques that appear to be safer include gastric banding and vagal nerve stimulators (82). However, the safety and efficacy of these procedures has not been evaluated over the long term.

Conclusion

The prevalence of obesity in childhood continues to increase throughout the world. Currently, obesity is the second-leading cause of preventable death, after cigarette smoking. If our children continue to gain weight at the current rates, obesity will soon become the leading cause of death in the United States. Although treatment strategies using pharmacologic agents and surgery are being investigated, earlier intervention and prevention strategies are more cost-effective.

Physicians should begin intervention and counseling on appropriate diet and exercise choices and portion sizes during infancy and continue counseling and close monitoring of BMI throughout childhood. Breastfeeding for the first 4–6 months of life should be promoted. Children need to be encouraged to eat nutritious foods and exercise regularly. A recent study done in a school setting, without parental involvement, showed that education of children about nutrition and the adverse effects of sweetened soft drinks on body weight resulted in improved food choices both at home and at school, with subsequent weight loss (83). This study suggests that public health campaigns targeted at children may be an effective means of approaching this problem and, if initiated, may herald the beginning of the end of the epidemic of obesity.

Since the recognition that the adipose tissue is an endocrine organ, more and more children with obesity are being referred to pediatric endocrinologists. With the increasing amount of pediatric obesity in the world, this influx of patients could conceivably overwhelm a practice. However, it is appropriate for an endocrinologist to care for children with the comorbidities of obesity, such as metabolic syndrome, type 2 diabetes, polycystic ovarian syndrome, and dyslipidemia. The best treatment strategy seems to be a multidisciplinary approach to the problem, involving an endocrinologist along with other subspecialists (such as cardiology, nephrology, and pulmonary), a nutritionist, a psychologist, and an exercise physiologist. Additionally, frequent follow-up of patients with obesity is absolutely necessary for success.

Acknowledgments

Received February 13, 2004. Accepted June 11, 2004.

Address all correspondence and requests for reprints to: Jennifer Miller, M.D., 1700 SW 16th Avenue, Gainesville, Florida 32608.

References

1. Kimm SY, Obarzanek E 2002 Childhood obesity: a new pandemic of the new millennium. *Pediatrics* 110:1003–1007
2. Thibault H, Rolland-Cachera MF 2003 Prevention strategies of childhood obesity. *Arch Pediatr* 10:1100–1108 (French)
3. Fox R 2003 Overweight children. *Circulation* 108:e9071 (Editorial)
4. Deitel M 2002 The International Obesity Task Force and “globesity.” *Obes Surg* 12:613–614
5. du Toit G, van der Merwe MT 2003 The epidemic of childhood obesity. *S Afr Med J* 93:49–50
6. Must A 2003 Does overweight in childhood have an impact on adult health? *Nutr Rev* 61:139–142
7. Magarey AM, Daniels LA, Boulton TJ, Cockington RA 2003 Predicting obesity in early adulthood from childhood and parental obesity. *Int J Obes Relat Metab Disord* 27:505–513
8. St-Onge MP, Heymsfield SB 2003 Overweight and obesity status are linked to lower life expectancy. *Nutr Rev* 61:313–316
9. Goran MI, Ball GD, Cruz ML 2003 Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. *J Clin Endocrinol Metab* 88:1417–1427
10. Wang G, Dietz WH 2002 Economic burden of obesity in youths aged 6 to 17 years: 1979–1999. *Pediatrics* 109:E81–1
11. Steinberger J, Daniels SR 2003 Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). *Circulation* 107:1448–1453
12. Livingstone MB, Robson PJ, Wallace JM, McKinley MC 2003 How active are we? Levels of routine physical activity in children and adults. *Proc Nutr Soc* 62:681–701
13. Saelens BE, Sallis JF, Nader PR, Broyles SL, Berry CC, Taras HL 2002 Home environmental influences on children’s television watching from early to middle childhood. *J Dev Behav Pediatr* 23:127–132
14. Proctor MH, Moore LL, Gao D, Cupples LA, Bradlee ML, Hood MY, Ellison RC 2003 Television viewing and change in body fat from preschool to early adolescence: The Framingham Children’s Study. *Int J Obes Relat Metab Disord* 27:827–833
15. Burgeson CR, Wechsler H, Brener ND, Young JC, Spain CG 2001 Physical education and activity: results from the School Health Policies and Programs Study 2000. *J Sch Health* 71:279–293
16. Troiano RP 2002 Physical inactivity among young people. *N Engl J Med* 347:706–707
17. Nielsen SJ, Popkin BM 2003 Patterns and trends in food portion sizes, 1977–1998. *JAMA* 289:450–453
18. Wilson N, Quigley R, Mansoor O 1999 Food ads on TV: a health hazard for children? *Aust NZ J Public Health* 23:647–650
19. St-Onge MP, Keller KL, Heymsfield SB 2003 Changes in childhood food consumption patterns: a cause for concern in light of increasing body weights. *Am J Clin Nutr* 78:1068–1073
20. Poulsen P, Vaag A 2003 The impact of genes and pre- and postnatal environment on the metabolic syndrome. Evidence from twin studies. *Panminerva Med* 45:109–115
21. Maes HH, Neale MC, Eaves LJ 1997 Genetic and environmental factors in relative body weight and human adiposity. *Behav Genet* 27:325–351
22. Neel J 1962 Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? *Am J Hum Genet* 14:353–362
23. Hales CN, Barker DJ 1992 Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. *Diabetologia* 35:595–601
24. Hales CN, Barker DJ 2001 The thrifty phenotype hypothesis. *Br Med Bull* 60:5–20
25. Srinivasan M, Laychock SG, Hill DJ, Patel MS 2003 Neonatal nutrition: metabolic programming of pancreatic islets and obesity. *Exp Biol Med* 228:15–23
26. Clifford TJ 2003 Breast feeding and obesity. *BMJ* 327:879–880
27. Parsons TJ, Power C, Manor O 2003 Infant feeding and obesity through the lifecourse. *Arch Dis Child* 88:793–794
28. Dewey KG 2003 Is breastfeeding protective against child obesity? *J Hum Lact* 19:9–18
29. Rajala MW, Scherer PE 2003 Minireview: the adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. *Endocrinology* 144:3765–3773
30. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S 2003 Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. *N Engl J Med* 348:1085–1095
31. Gunnell DJ, Frankel SJ, Nanchahal K, Peters TJ, Davey Smith G 1998 Childhood obesity and adult cardiovascular mortality: a 57-y follow-up study based on the Boyd Orr cohort. *Am J Clin Nutr* 67:1111–1118
32. Aye T, Levitsky LL 2003 Type 2 diabetes: an epidemic disease in childhood. *Curr Opin Pediatr* 15:411–415
33. Arslanian S 2002 Type 2 diabetes in children: clinical aspects and risk factors. *Horm Res* 57(Suppl 1):19–28
34. Rosenbloom AL 2002 Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations. *Paediatr Drugs* 4:209–221
35. Lipton R, Keenan H, Onyemere KU, Freels S 2002 Incidence and onset features of diabetes in African-American and Latino children in Chicago, 1985–1994. *Diabetes Metab Res Rev* 18:135–142
36. Wallerstein R 2002 Population genetics in minority children with type 2 diabetes mellitus. *J Pediatr Endocrinol Metab* 15(Suppl 1):485–486
37. Arslanian SA 2002 Metabolic differences between Caucasian and African-American children and the relationship to type 2 diabetes mellitus. *J Pediatr Endocrinol Metab* 15(Suppl 1):509–517
38. Sharp TA, Grunwald GK, Giltinan KE, King DL, Jatkauskas CJ, Hill JO 2003 Association of anthropometric measures with risk of diabetes and cardiovascular disease in Hispanic and Caucasian adolescents. *Prev Med* 37:611–616
39. Bogardus C, Tataranni PA 2002 Reduced early insulin secretion in the etiology of type 2 diabetes mellitus in Pima Indians. *Diabetes* 51(Suppl 1):S262–S264
40. Carter JS, Pugh JA, Monterrosa A 1996 Non-insulin dependent diabetes mellitus in minorities in the United States. *Ann Intern Med* 123:221–232

41. **Perneger TV, Whelton PK, Puddey IB, Klag MJ** 1994 End-stage renal disease attributable to diabetes mellitus. *Ann Intern Med* 121:912–918
42. **Murphy MJ, Metcalf BS, Voss LD, Jeffery AN, Kirkby J, Mallam KM, Wilkin TJ; The EarlyBird Study (EarlyBird 6)** 2004 Girls at five are intrinsically more insulin resistant than boys: The Programming Hypotheses Revisited-The EarlyBird Study (EarlyBird 6). *Pediatrics* 113:82–86
43. **Carnethon MR, Fortmann SP, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE** 2003 Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987–1998. *Am J Epidemiol* 158:1058–1067
44. **Schaffer JE** 2003 Lipotoxicity: when tissues overeat. *Curr Opin Lipidol* 14:281–287
45. **Diamond Jr FB, Eichler DC** 2002 Leptin and the adipocyte endocrine system. *Crit Rev Clin Lab Sci* 39:499–525
46. **Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K** 2003 Obesity, adiponectin and vascular inflammatory disease. *Curr Opin Lipidol* 14:561–566
47. **Grundey SM, Brewer Jr HB, Cleeman Jr SC, Lenfant C** 2004 Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. *Arterioscler Thromb Vasc Biol* 24:E13–E18
48. **Frontini MG, Srinivasan SR, Berenson GS** 2003 Longitudinal changes in risk variables underlying metabolic Syndrome X from childhood to young adulthood in female subjects with a history of early menarche: the Bogalusa Heart Study. *Int J Obes Relat Metab Disord* 27:1398–1404
49. **Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH** 2003 Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. *Arch Pediatr Adolesc Med* 157:821–827
50. **Davis PH, Dawson JD, Riley WA, Lauer RM** 2001 Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. *Circulation* 104:2815–2819
51. **Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, Jarvisalo MJ, Uhari M, Jokinen E, Ronnemaa T, Akerblom HK, Viikari JS** 2003 Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. *JAMA* 290:2277–2283
52. **Tracy RE, Newman 3rd WP, Wattigney WA, Berenson GS** 1995 Risk factors and atherosclerosis in youth autopsy findings of the Bogalusa Heart Study. *Am J Med Sci* 310(Suppl 1):S37–S41
53. **Zieske AW, Malcolm GT, Strong JP** 2002 Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. *Pediatr Pathol Mol Med* 21:213–237
54. **Poredos P** 2002 Endothelial dysfunction and cardiovascular disease. *Pathophysiol Haemost Thromb* 32:274–277
55. **Caballero AE** 2003 Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. *Obes Res* 11:1278–1289
56. **Tounian P, Aggoun Y, Dubern B, Varille V, Guy-Grand B, Sidi D, Girardet JP, Bonnet D** 2001 Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. *Lancet* 358:1400–1404
57. **Muller WA** 2003 Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. *Trends Immunol* 24:327–334
58. **Fan J, Watanabe T** 2003 Inflammatory reactions in the pathogenesis of atherosclerosis. *J Atheroscler Thromb* 10:63–71
59. **Aldhahi W, Hamdy O** 2003 Adipokines, inflammation, and the endothelium in diabetes. *Curr Diab Rep* 3:293–298
60. **Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, Ueda S, Shimomura I, Funahashi T, Matsuzawa Y** 2003 Hypoadiponectinemia is closely linked to endothelial dysfunction in man. *J Clin Endocrinol Metab* 88:3236–3240
61. **Ukkola O, Santaniemi M** 2002 Adiponectin: a link between excess adiposity and associated comorbidities? *J Mol Med* 80:696–702
62. **Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H, Kishida K, Maeda N, Nagasawa A, Kobayashi H, Hiraoka H, Komai N, Kaibe M, Rakugi H, Ogiwara T, Matsuzawa Y** 2003 Association of hypoadiponectinemia with impaired vasoreactivity. *Hypertension* 42:231–234
63. **Cummings S, Parham ES, Strain GW** 2002 Position of the American Dietetic Association: weight management. *J Am Diet Assoc* 102:1145–1155
64. **Jakicic JM** 2003 Exercise in the treatment of obesity. *Endocrinol Metab Clin North Am* 32:967–980
65. **Centers for Disease Control and Prevention** 2003 Prevalence of physical activity, including lifestyle activities among adults—United States, 2000–2001. *MMWR Morb Mortal Wkly Rep* 52:764–769
66. **Agnew B** 2002 Simple steps to fitness. Barriers to exercise (and how to get past them). Everything from time constraints to safety concerns can discourage you from exercising. Don't let them! *Diabetes Forecast* 55:89–90, 92
67. 2003 Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease. *J Cardiovasc Risk* 10:429–437
68. **Moyna NM, Thompson PD** 2004 The effect of physical activity on endothelial function in man. *Acta Physiol Scand* 180:113–123
69. **Ishikawa-Takata K, Ohta T, Tanaka H** 2003 How much exercise is required to reduce blood pressure in essential hypertensives: a dose-response study. *Am J Hypertens* 16:629–633
70. **Miller WC** 1999 How effective are traditional dietary and exercise interventions for weight loss? *Med Sci Sports Exerc* 31:1129–1134
71. **Roberts CK, Barnard RJ** 2003 Low-carbohydrate diets as compared with low-fat diets. *N Engl J Med* 349:1000–1002
72. **Moore LL, Daniels S** 2004 Weight-loss diets designed for adults may cause children to gain weight. 44th Annual American Heart Association Conference on Cardiovascular Disease Epidemiology and Prevention (Abstract)
73. **Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S** 2003 A randomized trial of a low-carbohydrate diet for obesity. *N Engl J Med* 348:2082–2090
74. **Aziz I** 2003 Low-carbohydrate diets as compared with low-fat diets. *N Engl J Med* 349:1000–1002
75. **Leung WY, Neil Thomas G, Chan JC, Tomlinson B** 2003 Weight management and current options in pharmacotherapy: orlistat and sibutramine. *Clin Ther* 25:58–80
76. **Thearle M, Aronne LJ** 2003 Obesity and pharmacologic therapy. *Endocrinol Metab Clin North Am* 32:1005–1024
77. **Padwal R, Li S, Lau D** 2003 Long-term pharmacotherapy for obesity and overweight. *Cochrane Database Syst Rev* 4:CD004094
78. **Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH** 2003 A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. *Obes Res* 11:722–733
79. **Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR** 2003 Inhibition of food intake in obese subjects by peptide YY3–36. *N Engl J Med* 349:941–948
80. **Despres JP** 2003 Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. *Diabetes Metab* 29:6553–6561
81. **Fisher BL, Schauer P** 2002 Medical and surgical options in the treatment of severe obesity. *Am J Surg* 184:9S–16S
82. **Weiner R, Blanco-Engert R, Weiner S, Matkowitz R, Schaefer L, Pomhoff I** 2003 Outcome after laparoscopic adjustable gastric banding—8 years experience. *Obes Surg* 13:427–434
83. **James-Jak D** 2003 Implicating sugar-sweetened soda in the aetiology of childhood obesity. New Orleans, LA, June 2003. American Diabetes Association Presentation (Abstract 302-OR)

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.